Bristol Myers Squibb to acquire Mirati in a $4.8 billion deal
Bristol-Myers Squibb is set to acquire cancer drugmaker Mirati Therapeutics for $58 per share in cash, representing $4.8 billion equity value.
Source link
- Women’s fencing sets high expectations for season – The Denisonian
- No place for Gaza residents to flee after Israel declares war, bombs homes
